| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -20.4 | -4.6 |
| EPS (diluted, $ a share) | $-0.79 | $-3.62 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: FTH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Faeth Therapeutics, Inc.: key numbers
- Share price
- $9.28Close, Nov 16
- Market cap
- $240M
- Shares outstanding
- 25.84MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Faeth Therapeutics, Inc.
All →Faeth Therapeutics Clinical Trial Data
Faeth Therapeutics announced topline clinical data from its Phase 2 PIK-201 trial evaluating its product candidate PIKTOR in patients with advanced endometrial cancer. The trial evaluated PIKTOR (a combination of serabelisib and sapanisertib) in combination with paclitaxel. The company released a corporate presentation detailing these preliminary efficacy and safety results to investors.
Faeth Therapeutics Clinical Trial Data
Faeth Therapeutics reported positive topline Phase 2 results from its PIK-201 trial evaluating PIKTOR in combination with paclitaxel for advanced endometrial cancer. The trial achieved a 33% confirmed objective response rate (ORR) and a median progression-free survival of 7.4 months, supporting the company's plan to advance the program into a Phase 3 registrational trial.
- Counterparty
- The GOG Foundation, Inc.
Faeth Therapeutics Financial Results
Faeth Therapeutics reported third quarter 2026 financial results, ending the period with $174.8 million in cash and marketable securities. The company highlighted the receipt of FDA Fast Track designation for its lead program PIKTOR in endometrial cancer and expects topline Phase 2 data by year-end 2026.
- Term
- Q3 2026
“We designed PIKTOR, an all-oral, multi-node inhibitor, to address those limitations, and we believe it has the potential to give patients a differentiated treatment option. We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer by year-end, and to reporting initial safety and efficacy data from our PIK-101 trial in HR+/HER2- breast cancer in 2027.”
Anand Parikh, Chief Executive Officer
Faeth Therapeutics Leadership Change
Faeth Therapeutics increased its board size from six to seven and appointed Adam Schayowitz, Ph.D., as a Class III director. Dr. Schayowitz, currently EVP and Head of R&D at Zymeworks, brings extensive oncology drug development experience from previous roles at Pfizer and Tesaro. He will receive a standard non-employee director compensation package, including an initial option to purchase 25,000 shares of common stock.
Faeth Therapeutics Leadership Change
Faeth Therapeutics increased its board size from five to six and appointed co-founder Karen Vousden, Ph.D., as a Class II director and member of the Compensation Committee. Dr. Vousden, a renowned cancer biologist and current director at Bristol Myers Squibb, will receive a standard non-employee director compensation package including an option to purchase 25,000 shares of common stock.
- Counterparty
- Karen Vousden, Ph.D.